WHO broadens contraception guidance across pills, implants and emergency options

On 23 September WHO added guidance on extended or continuous combined pills, longer etonogestrel-implant use and mifepristone for emergency contraception.

It called for more safety evidence on ormeloxifene and advised against adding quinestrol pills to national programmes because evidence is limited and serious adverse events have been reported.

How long?

Combined pills may be used in extended cycles up to six months or continuously up to one year; WHO supports etonogestrel implants for up to five years.

Emergency option

Mifepristone 10–50 mg is recommended as an additional option as soon as possible and within five days after unprotected sex. Availability is not automatic in every country.

Why choice matters

WHO estimates 164 million women wanting to delay or avoid pregnancy are not using contraception. More options may better match cost, visits, preferences and side effects.

What to check

Confirm the product, licensed duration, personal contraindications and local rules with a clinician. The guideline supports policy and clinical guidance; it does not replace individual care.

Primary source and independent checks

Primary source: WHO ECO guideline

Institutional explanation: WHO news release

Independent check: Quotidiano Sanità

Read in other languages

한국어 · English · Español · 日本語 · Tiếng Việt